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CliBACKGROUND The American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol management
guidelines have signiﬁcantly broadened the scope of candidates eligible for statin therapy.
OBJECTIVES This study evaluated the implications of the absence of coronary artery calcium (CAC) in reclassifying
patients from a risk stratum in which statins are recommended to one in which they are not.
METHODS MESA (Multi-Ethnic Study of Atherosclerosis) is a longitudinal study of 6,814 men and women 45 to
84 years of age without clinical atherosclerotic cardiovascular disease (ASCVD) risk at enrollment. We excluded 1,100
participants (16%) on lipid-lowering medication, 87 (1.3%) without low-density lipoprotein levels, 26 (0.4%) with
missing risk factors for calculation of 10-year risk of ASCVD, 633 (9%) >75 years of age, and 209 (3%) with low-density
lipoprotein <70 mg/dl from the analysis.
RESULTS The study population consisted of 4,758 participants (age 59  9 years; 47% males). A total of 247 (5.2%)
ASCVD and 155 (3.3%) hard coronary heart disease events occurred over a median (interquartile range) follow-up of 10.3
(9.7 to 10.8) years. The new ACC/AHA guidelines recommended 2,377 (50%) MESA participants for moderate- to high-
intensity statins; the majority (77%) was eligible because of a 10-year estimated ASCVD risk $7.5%. Of those recom-
mended statins, 41% had CAC ¼ 0 and had 5.2 ASCVD events/1,000 person-years. Among 589 participants (12%)
considered for moderate-intensity statin, 338 (57%) had a CAC ¼ 0, with an ASCVD event rate of 1.5 per 1,000 person-
years. Of participants eligible (recommended or considered) for statins, 44% (1,316 of 2,966) had CAC ¼ 0 at baseline
and an observed 10-year ASCVD event rate of 4.2 per 1,000 person-years.
CONCLUSIONS Signiﬁcant ASCVD risk heterogeneity exists among those eligible for statins according to the
new guidelines. The absence of CAC reclassiﬁes approximately one-half of candidates as not eligible for statin therapy.
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1658I n 2014, the American College of Cardiol-ogy (ACC) and the American HeartAssociation (AHA) accentuated the im-
portance of atherosclerotic cardiovascular
disease (ASCVD) risk derived from the Pooled
Cohort Equations in determining candidates
for statin therapy (1,2). It is estimated that
45 million middle-aged adults in the United
States free of established cardiovascular dis-
ease (CVD) are now recommended or con-
sidered for statins on the basis of their
estimated 10-year ASCVD risks of $7.5%
and 5% to 7.5%, respectively (1). The implica-
tion for widening the scope of those eligible
for statins has been widely debated (3–5).
Because the net beneﬁt from treatment is
directly proportional to the absolute risk (1),
many of those newly eligible for statins willlikely not accrue a large absolute reduction in risk
from treatment. With a signiﬁcant increase in the
population eligible for treatment, accurate identiﬁca-
tion of low-risk statin candidates who are less likely
to yield meaningful beneﬁts is critical to facilitate
appropriate resource allocation and shared decision-
making processes.SEE PAGES 1654 AND 1669Coronary artery calcium (CAC), detected by low
radiation, noncontrast cardiac computed tomography
testing, estimates the burden of coronary atheroscle-
rosis and is a method for further risk stratiﬁcation in
the primary prevention setting (6,7). Increased CAC is
associated with almost a 10-fold higher risk of adverse
ASCVD events, independent of the baseline traditional
risk proﬁle (6,7). More importantly, the absence of CAC
in an asymptomatic adult confers a very low risk for
future cardiac events (8–11). This can potentially allow
patient choices to focus on low-cost lifestyle modiﬁ-
cations and the pursuit of ﬂexible treatment goals.
In this study, we speciﬁcally aimed to determine
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eligible for statin therapy move to a category in which
the guideline no longer recommends treatment.
These results can have important implications for
public health discussions aimed at improving the
efﬁciency and cost-effectiveness of statin use in
primary prevention settings.
METHODS
STUDY PARTICIPANTS. Full details of the MESA
(Multi-Ethnic Study of Atherosclerosis) study design
have been published previously (12). MESA is a pro-
spective observational cohort of 6,814 men and
women, 45 to 84 years of age, without known CVD at
enrollment. Participants were enrolled from July 2000
through September 2002 at 6 different ﬁeld centers in
the United States (Baltimore, Maryland; Chicago, Illi-
nois; Forsyth County, North Carolina; Los Angeles,
California; New York, New York; and St. Paul, Minne-
sota). Participants identiﬁed themselves as white,
black, Chinese, or Hispanic at the time of enrollment.
All participants gave written informed consent.
RISK FACTORS. As part of the baseline examination,
staff at each of the 6 centers collected information
about cardiovascular risk factors. Total cholesterol,
high-density lipoprotein cholesterol, and triglyceride
measurements were performed at the Collaborative
Studies Clinical Laboratory at Fairview-University
Medical Center (Minneapolis, Minnesota) in blood
samples obtained after a 12-h fast. Diabetes was de-
ﬁned as fasting blood glucose$7.0mmol/l (126mg/dl),
self-reported diabetes, or use of hypoglycemic drugs.
Hypertension was deﬁned as untreated diasto-
lic blood pressure $90 mm Hg, systolic blood pressure
$140 mm Hg, or use of antihypertensive medication.
Smoking was deﬁned as current use of cigarettes.
The 10-year risk of hard ASCVD events for MESA
participants was calculated on the basis of age,
total cholesterol and high-density lipoprotein chol-
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FIGURE 1 Statin Eligibility Among the Baseline Study Population
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Overall, 50% of the study population was recommended for moderate- to high-intensity statin, 12% was considered for statin, and 38% was not eligible for
statin therapy. ASCVD ¼ atherosclerotic cardiovascular disease; LDL ¼ low-density lipoprotein.
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1659hypertension, current smoking, and history of dia-
betes mellitus, using the race-/sex-speciﬁc parame-
ters from the ACC/AHA Pooled Cohort Equations with
Hispanics/Chinese calculated as white (2).
STATIN ELIGIBILITY. On the basis of the ACC/AHA
guidelines, MESA participants were classiﬁed into the
following groups for statin eligibility (1).
1. Statin recommended: In accordance with strong
evidence from randomized controlled trials sug-
gesting that the reduction in ASCVD events from
statin therapy exceeds adverse events when used
in primary prevention.
a. Low-density lipoprotein cholesterol (LDL-C)
levels $190 mg/dl
b. Diabetes and LDL-C levels between 70 and
189 mg/dl
c. Without diabetes and with a 10-year ASCVD
risk $7.5% and LDL-C levels between 70 and
189 mg/dl2. Statin considered: Moderate evidence supports
consideration of statin therapy for primary pre-
vention in participants with a 10-year ASCVD risk
of 5% to <7.5% (1).
CAC SCORE MEASUREMENTS. TheMESAmethods for
computed tomography scanning and interpretation
were published previously (13). All participants were
scanned twice, with mean CAC (Agatston) score used
for all analyses (14). Estimates of radiation dose
determined according to theMESA protocol for a single
scan obtained through the heartwith the Imatron C150,
Volume Zoom, and LightSpeed Pro 16 scanners were as
follows: 0.6 and 0.7, 0.9 and 1.1, and 0.9 and 1.1 mSv for
men and women, respectively (15). Participants were
told that they had no CAC or that it was less than
average, average, or greater than average, and that
they should discuss the results with their physicians.
ASCERTAINMENT OF ASCVD EVENTS. At intervals of
9 to 12 months, an interviewer contacted each
TABLE 1 Baseline Characteristics of Study Population
Statin
Recommended
(n ¼ 2,377)
Statin
Considered
(n ¼ 589)
Statin Not
Recommended
(n ¼ 1,792) p Value
Age, yrs 64.7  7.3 58.4  6.5 52.4  5.6 <0.001
Male 1,434 (60) 299 (51) 506 (28) <0.001
Race <0.001
White 795 (33) 220 (37) 772 (43)
Black 791 (33) 180 (31) 326 (18)
Hispanic 534 (23) 124 (21) 437 (25)
Asian 257 (11) 65 (11) 257 (14)
Diabetes 472 (20) 0 (0) 0 (0) <0.001
Hypertension 1,439 (61) 194 (33) 317 (18) <0.001
Smoking <0.001
Never 1,023 (43) 280 (47) 1,079 (60)
Former 918 (39) 211 (36) 569 (32)
Current 436 (18) 98 (17) 144 (8)
Education <0.001
<High school 1,306 (56) 290 (50) 758 (43)
College 291 (12) 71 (12) 256 (14)
Bachelor or above 753 (32) 224 (38) 764 (43)
Family history of CHD 948 (43) 237 (43) 652 (38) 0.002
BMI, kg/m2 28.7  5.3 28.5  5.4 27.8  5.8 <0.001
Total cholesterol, mg/dl 201.5  34.8 199.8  30.6 195.1  29.4 <0.001
LDL-C, mg/dl 126.4  31.2 124.6  26.4 117.7  25.5 <0.001
HDL-C, mg/dl 48.5  13.8 49.9  13.9 54.5  15.2 <0.001
Triglycerides, mg/dl 132.8  67.0 126.4  64.4 114.5  59.1 <0.001
Values are mean  SD or n (%).
BMI ¼ body mass index; CHD ¼ coronary heart disease; HDL-C ¼ high-density lipoprotein cholesterol;
LDL-C ¼ low-density lipoprotein cholesterol.
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1660participant or family member by telephone to inquire
about interim hospital admissions, outpatient
diagnoses of coronary heart disease (CHD) and CVD,
and deaths. A MESA study committee of cardiologists,
physician epidemiologists, and neurologists adjudi-
cated ASCVD events. In the event of disagreement,
the full committee made the ﬁnal classiﬁcation. MESA
was successful in obtaining medical records for
approximately 98% of reported hospitalized CHD and
CVD events and information on 95% of reported
outpatient cardiovascular diagnostic encounters.
Follow-up telephone interviews were completed in
92% of living participants.
For the purpose of this study, CHD events were
classiﬁed as myocardial infarction, resuscitated car-
diac arrest, or CHD death. ASCVD events included
CHD events plus nonfatal and fatal strokes. Transient
ischemic attacks were not included. The diagnosis of
myocardial infarction was on the basis of a combina-
tion of symptoms, electrocardiographic ﬁndings, and
levels of cardiac biomarkers. We used hospital re-
cords and family interviews to determine whether
deaths were related to CHD. A death was considered
related to CHD if it occurred within 28 days after a
myocardial infarction, if the participant had chestpain within 72 h before death, or if the participant had
a history of CHD and there was no known non-
atherosclerotic, noncardiac cause of death. Stroke
was on the basis of rapid onset of a documented focal
neurological deﬁcit lasting 24 h or until death or,
if <24 h, with accompanying evidence of a clinically
relevant lesion on brain imaging. Study participants
with focal neurological deﬁcits secondary to brain
trauma, tumor, infection, or other nonvascular cause
were excluded. A more detailed description of the
MESA follow-up methods is available at the MESA
website (16).
STATISTICAL ANALYSIS. Baseline characteristics of
the study participants were analyzed according to
statin eligibility criteria. Frequencies and proportions
were calculated for categorical variables, and either
means with standard deviations or medians with
interquartile ranges were calculated for continuous
variables. Chi-square tests and 1-way analysis of
variance were used for comparison of variables be-
tween groups. We used Kaplan-Meier estimates of
cumulative event-free survival to describe the occur-
rence of ASCVD and CHD events over time. To deter-
mine if CAC can further stratify risk in statin eligibility
groups, we compared ASCVD and CHD event rates,
as well as Cox multivariable-adjusted hazard ratios,
after stratifying by the CAC categories listed previ-
ously. Models were adjusted for age, sex, race/
ethnicity, education level, and MESA site. A 10-year
number needed to treat (NNT10) for LDL-C lowering
by statins was estimated for both ASCVD and CHD by
applying the hazard ratio associated with the expected
relative event reduction of 30% with a 1.0 mmol/l
reduction in LDL-C on the basis of a Cochrane meta-
analysis (17) of statin therapy in primary prevention.
The NNT10 was calculated directly as the reciprocal of
the absolute risk difference at the median follow-up of
the cohort on the basis of Kaplan-Meier estimates and
was subsequently adjusted to a NNT10 according to the
Altman-Anderson method (18).
RESULTS
Of 6,814 participants at baseline, participants were
excluded from the analysis as follows: 1,100 (16%) on
lipid-lowering medication; 87 (1.3%) with absent LDL
levels; 27 (0.4%) with missing risk factors for calcu-
lation of the 10-year risk of ASCVD using the new
Pooled Cohort Equations; 633 (9%) age >75 years; and
209 (3%) with LDL <70 mg/dl.
STATIN ELIGIBILITY ACCORDING TO ACC/AHA
CHOLESTEROL MANAGEMENT GUIDELINES. The
ﬁnal study population consisted of 4,758 participants
(59  9 years, 47% males), among whom 2% (n ¼ 94)
FIGURE 2 CAC Distribution Across Statin Eligibility Groups
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CAC scores at baseline across statin-eligible groups according to the ACC/AHA Cholesterol
Management Guidelines. The absence of CAC was noted in 44% (1,316 of 2,966) of statin
candidates (considered or recommended). ACC/AHA ¼ American College of Cardiology/
American Heart Association; CAC ¼ coronary artery calcium.
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1661had LDL-C $190 mg/dl and 10% (n ¼ 461) had dia-
betes with LDL-C 70 to 189 mg/dl and were eligible
for moderate- to high-intensity statins (Figure 1).
According to the ACC/AHA guidelines, 38% (n ¼
1,822) nondiabetic patients with LDL-C 70 to
189 mg/dl were eligible for moderate- to high-
intensity statins because of their 10-year estimated
ASCVD risk $7.5% (Figure 1). As a result, in total,
50% (n ¼ 2,377) of the study participants were rec-
ommended statins. In addition, 589 (12%) were
considered for moderate-intensity statins (nondia-
betic patients, LDL-C 70 to 189 mg/dl and 10-year
ASCVD risk 5% to 7.5%). Baseline characteristics of
the study population according to statin eligibility
are shown in Table 1.
DISTRIBUTION OF CAC ACCORDING TO STATIN
ELIGIBILITY CRITERIA. Of the participants included
in the analysis, 2,733 (58%) had CAC ¼ 0, whereas
1,196 (25%) had CAC between 1 and 100 and 829 (17%)
had CAC $100. The distribution of CAC according to
statin-eligible groups is shown in Figure 2. Overall,
41% of MESA participants recommended for moder-
ate- to high-intensity statins by ACC/AHA guidelines
had CAC ¼ 0. More than one-half (57%) of MESA
participants considered for moderate-intensity sta-
tins (n ¼ 338) had no detectable CAC. Conversely,
only 21% (n ¼ 375) who were not candidates for sta-
tins had CAC >0, with 4% demonstrating elevated
CAC >100 (Figure 2).
STATIN ELIGIBILITY AND INCIDENT CARDIOVASCULAR
EVENTS. Over a median (interquartile range) follow-
up of 10.3 (9.7 to 10.8) years, 247 (5.2%) ASCVD and
155 (3.3%) hard CHD events were observed. The
ASCVD rate was 9.1 per 1,000 person-years (95%
conﬁdence interval [CI]: 7.9 to 10.5) for those rec-
ommended statins as compared with 4.00 (95% CI:
2.6 to 6.0) among those considered for statins and
1.62 (95% CI: 1.2 to 2.3) per 1,000 person-years among
those who were not statin candidates. The respective
CHD event rates in these groups were 5.5 (95% CI:
4.6 to 6.6), 2.4 (95% CI: 1.4 to 4.1), and 1.2 (95% CI:
0.8 to 1.8).
INCIDENT CARDIOVASCULAR EVENTS ACCORDING TO
CACSCORESACROSSSTATIN-ELIGIBLEGROUPS. Figure 3
shows Kaplan-Meier estimates of event-free survival
for ASCVD and CHD among the population by CAC
burden among groups according to statin eligibility
criteria. The frequency of observed ASCVD and CHD
events, the corresponding event rates per 1,000
person-years, and the multivariable-adjusted HRs
associated with the prevalence and burden of CAC in
MESA participants across statin eligibility criteria are
detailed in Table 2. Among the 41% of participantsrecommended for statins with CAC ¼ 0, ASCVD events
in 4.9% were noted as corresponding to 5.2 events per
1,000 person-years of follow-up. The respective
ASCVD event rate among study participants consid-
ered for statins with CAC ¼ 0 was 1.5 person-years.
Overall, 44% (1,316 of 2,966) of statin-eligible (rec-
ommended or considered) candidates had CAC ¼ 0 at
baseline, with a subsequent ASCVD event rate of 4.2
per 1,000 person-years. In contrast, the presence of
any CAC (56%) was associated with an ASCVD event
rate of 11.2 per 1,000 person-years. In comparison,
among participants not eligible for statins, the ASCVD
event rates with any CAC present (21%) or CAC >100
(4%) were 2.7 per 1,000 person-years and 9.6 per
1,000 person-years, respectively (Table 2).
Figure 4 highlights the distribution of CAC burden
across increasing 10-year ASCVD risk-score cutoffs
among nondiabetic participants with LDL-C 70 to 189
mg/dl recommended for statins on the basis of their
10-year ASCVD risk $7.5% (n ¼ 1,822). Figures 5A and
5B show that the lowest event rates were noted in
those with CAC ¼ 0 across increasing 10-year ASCVD
risk estimates. Overall, 45% (618 of 1,381) of partici-
pants with 10-year ASCVD risks of 7.5% to 20% had
CAC ¼ 0, and corresponding observed 10-year ASCVD
event rates of 4.6 per 1,000 person-years (Central
Illustration). The respective ASCVD event rate with
the presence of CAC in this group was 10.4 per 1,000
person-years. Conversely, among participants with
estimated risk >20% (n ¼ 441), absence of CAC was
FIGURE 3 Kaplan-Meier Survival Curves Free of ASCVD and CHD With Increasing CAC Scores Across Statin Eligibility Groups
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Overall, the fewest events were observed with CAC ¼ 0 in each group. (A) Survival from ASCVD events with increasing CAC score in 10-year follow-up
among statin-eligible groups according to the ACC/AHA Cholesterol Management Guidelines. (B) Survival free of CHD events with increasing CAC scores in
10-year follow-up among statin-eligible groups according to the ACC/AHA Cholesterol Management Guidelines. CHD ¼ coronary heart disease; CVD ¼
cardiovascular disease; other abbreviations as in Figures 1 and 2.
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1662noted in 26% (Figure 4), and the observed ASCVD risk
was above the threshold recommended for treatment
(11.7 per 1,000 person-years).
ESTIMATED NUMBER NEEDED TO TREAT TO PREVENT
1 CARDIOVASCULAR EVENT. As shown in Table 3,
applying a 30% relative risk reduction associated with
statin therapy, the NNT10 to prevent an ASCVD inparticipants recommended for statins was 64 for those
with CAC ¼ 0 and 28 for those with CAC >100. The
corresponding NNT10 in those considered for statins
was 223 for those with CAC ¼ 0 and 46 for those with
CAC >100. When considering prevention of CHD,
NNT10 in the absence of CAC was 139 among candi-
dates recommended for statins and 556 for those
considered for statins. Similar results were noted
TABLE 2 ASCVD and CHD Outcomes With CAC Across Statin Eligibility Groups
N
ASCVD CHD
Events (%)
Event Rate
Per 1,000
Person-Years
(95% CI) HR (95% CI) Events (%)
Event Rate
Per 1,000
Person-Years
(95% CI) HR (95% CI)
Statin recommended 2,377
CAC ¼ 0 978 48 (4.9) 5.2 (4.0–7.0) Reference group 22 (2.3) 2.4 (1.6–3.6) Reference group
CAC 1-100 714 56 (7.9) 8.8 (6.8–11.4) 1.64 (1.11–2.43) 37 (5.2 ) 5.7 (4.1–7.9) 2.2 (1.3–3.8)
CAC >100 685 91 (13.3) 15.4 (12.5–18.9) 2.88 (1.97–4.21) 61 (8.9) 10.0 (7.8–12.8) 3.7 (2.2–6.3)
Any CAC present 1,399 147 (10.5) 12.0 (10.2–14.1) 2.15 (1.53–3.04) 98 (7.0) 7.8 (6.4–9.5) 2.9 (1.8–4.6)
Statin considered 589
CAC ¼ 0 338 5 (1.5) 1.5 (0.6–3.6) Reference group 2 (0.6) 0.6 (0.2–2.4) Reference group
CAC 1-100 184 14 (7.6) 7.8 (4.6–13.2) 5.45 (1.90–15.6) 9 (4.9) 5.0 (2.6–9.6) 7.5 (1.5–36.6)
CAC>100 67 4 (6.0) 6.3 (2.4–16.8) 4.23 (1.10–16.2) 3 (4.5) 4.7 (1.5–14.4) 8.2 (1.3–51.5)
Any CAC present 251 18 (7.2) 7.4 (4.7–11.8) 5.11 (1.8–14.1) 12 (4.8) 4.9 (2.8–8.6) 7.7 (1.7–35.9)
Statin not recommended 1,792
CAC ¼ 0 1,417 19 (1.3) 1.3 (0.9–2.1) Reference group 13 (0.9) 0.9 (0.5–1.6) Reference group
CAC 1-100 298 3 (1.0) 1.0 (0.3–3.1) 0.7 (0.2–2.3) 1 (0.3) 0.3 (0.1–2.3) 0.3 (0.4–2.5)
CAC >100 77 7 (9.1) 9.6 (4.6–20.2) 6.1 (2.4–15.6) 7 (9.1) 9.6 (4.6–20.1) 8.9 (3.2–24.4)
Any CAC present 375 10 (2.7) 2.7 (1.4-5.0) 1.7 (0.7–3.9) 8 (2.1) 2.1 (1.0–4.3) 1.8 (0.78-4.9)
Adjusted for age, sex, race, MESA site, and education status (CAC ¼ 0 was the reference group). Statin recommended: patients 45 to 75 years of age with primary elevations of
LDL-C $190 mg/dl, or diabetes and LDL-C 70 to 189 mg/dl, or nondiabetic patient with LDL-C 70 to 189 mg/dl and an estimated 10-year ASCVD risk of 7.5% or higher. Statin
considered: 10-year ASCVD risk 5% to <7.5%, Statin not recommended: 10-year ASCVD risk <5%.
ASCVD ¼ atherosclerotic cardiovascular disease; CAC ¼ coronary artery calcium; CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; LDL-C ¼ low-
density lipoprotein cholesterol; MESA ¼ Multiethnic Study of Atherosclerosis.
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1663across increasing risk categories among those with
ASCVD risk >7.5% (Online Table 1). Online Tables 2
and 3 highlight the results of the sensitivity analyses
for the estimated NNT10 among statin-eligible groups
as well as increased ASCVD risk estimates.
INCIDENT CARDIOVASCULAR EVENTS ACCORDING TO
CAC SCORES AMONG PATIENTSWITH DIABETES. Among
patients with diabetes with LDL-C 70 to 189 mg/dl,
the absence of CAC was associated with an ASCVD
event rate of 4.9 per 1,000 person-years and a corre-
sponding NNT10 of 69 to prevent 1 event. The
respective ASCVD event rate and NNT10 among those
with CAC >0 was 14.7 per 1,000 person-years and
23 (Online Table 4).
INCIDENT CARDIOVASCULAR EVENTS ACCORDING
TO CAC SCORES AMONG THE ELDERLY (>75 YEARS)
AND THOSE WITH LOW LDL-C (<70 mg/dl). In our
study, among 633 participants >75 years of age who
were excluded from analysis, almost all (99%) were
recommended for statins, as per ACC/AHA cholesterol
management guidelines. Overall, 18% of these elderly
participants had CAC ¼ 0, whereas 30% and 52% had
CAC between 1 and 100 and CAC >100, respectively.
The respective 10-year event rates across these CAC
categories were 6.7 per 1,000, 18.0 per 1,000, and 26.8
per 1,000 person-years.
Among study participants with LDL-C <70 mg/dl
who were excluded from the primary analysis, themajority (67%) had CAC ¼ 0, whereas 21% had CAC 1
to 100 and 12% had CAC >100. Overall, the revised
risk above the threshold for considering statins was
only noted in those with CAC >100 (10-year observed
ASCVD event rates for CAC ¼ 0: 2.9 per 1,000 person-
years; CAC 1 to 100: 2.6 per 1,000 person-years; and
CAC >100: 9.5 per 1,000 person-years).
DISCUSSION
When applying the 2013 ACC/AHA cholesterol treat-
ment guidelines (1), we noted that nearly two-thirds
of MESA participants 45 to 75 years of age without
known CVD are potentially eligible for statins (rec-
ommended or considered). Approximately one-half of
these statin-eligible candidates had CAC ¼ 0 and, as a
group, had a lower 10-year observed ASCVD risk than
the threshold recommended for treatment. The ma-
jority of ASCVD events occurred among those with
detectable CAC, consistent with 10-year risk levels
suggested by ACC/AHA cholesterol management
guidelines for statin therapy.
Since the release of the ACC/AHA cholesterol man-
agement guidelines in 2013, the central role of 10-year
ASCVD risk estimation in guiding statin eligibility has
received considerable attention (3–5). Recent studies
have demonstrated that the impact of the updated
recommendations will be higher treatment rates
among those expected to have future cardiovascular
FIGURE 4 CAC Distribution Across the Spectrum of 10-Year Risk Scores Among Those
With a 10-Year ASCVD Risk >7.5%
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Display of CAC score at baseline across increasing ASCVD risk estimates among non-
diabetics with LDL 70 to 189 mg/dl (n ¼ 1,822). Of these study participants, 1,381 of 1,822
(76%) had a 10-year estimated ASCVD risk of 7.5% to 20%, with an absence of CAC at
baseline noted in 45%. Abbreviations as in Figures 1 and 2.
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rotic burden, as compared with prior guidelines (20).
However, we are also challenged to treat a signiﬁcant
proportion of patients in low-risk groups, who may
derive minimal beneﬁt from these therapies. Accurate
risk assessment that can identify these lower-risk
subjects can potentially have a profound impact in
facilitating appropriate resource allocation and shared
decision-making to allow ﬂexible treatment choices.
Our study results suggest that the absence of CAC
can potentially overcome these challenges by
providing incremental information that may move
many people from risk levels that are recommended
for treatment to risk levels that are not. This obser-
vation is consistent with prior reports highlighting
the value of the absence of CAC (power of zero). In a
pooled analysis of more than 71,000 patients with
CAC ¼ 0, only 0.5% of participants suffered an adverse
event in a 4.2-year follow-up (8). In the prospective
MESA and Heinz Nixdorf Recall cohorts, only 1%
of participants had a hard CHD event during 5 years
of follow-up (6,7). Furthermore, CAC ¼ 0 has also
been associated with a much more favorable prog-
nosis, even among groups traditionally considered at
higher risk (9–11,21). Our current study adds to the
literature by demonstrating that the absence of CAC
is associated with a meaningfully lower ASCVD
risk among those deemed as statin candidates in afollow-up extending to 10 years. Among 41%whowere
recommended moderate- to high-intensity statins and
who had no detectable CAC, only 4.9% experienced an
ASCVD event. Furthermore, in those considered for
statins (10-year risk of 5% to 7.5%), the absence of CAC
was noted in a much larger proportion (57%), with an
extremely low 10-year ASCVD risk of 1.5%.
These ﬁndings may have important implications.
The patient-centered emphasis within the guidelines
recognizes that thresholds identiﬁed for treatment do
not mandate a statin prescription, but rather call for a
discussion between providers and patients to foster
informed decisions regarding initiation of statin
therapy (1). The process by which individual patients
reach an informed choice when considering a statin
medication for the next 10 years, in which they bal-
ance concerns of side effects, costs, and burden of use,
is also inﬂuenced by the estimate of the absolute risk
reduction likely to be achieved (1,22–24). As the ab-
solute ASCVD risk decreases, so does the net beneﬁt of
any intervention with a relative risk reduction that
does not increase with lower patient risk. In these
circumstances, the absence of CAC can afford signiﬁ-
cant value in promoting shared decision-making and
better informing patients, who may consider avoiding
statins to focus on prudent lifestyle changes, of their
choices.
Our study ﬁndings also suggest that CAC testing
may have limited impact on decisions regarding statin
utilization in a meaningful manner at the extremes of
calculated 10-year ASCVD risk. For example, among
MESA participants with a 10-year ASCVD risk <5%, we
noted an extremely low 10-year event rate of 1.6%.
The majority (79%) of these participants have CAC ¼ 0.
The presence of mild CAC (1 to 100) did not result in
reclassifying ASCVD risk above 5%, with only 4% of
participants with CAC >100 having an observed
ASCVD risk above the threshold for statin eligibility.
Although the current guidelines suggest that CAC
testing can be considered in selected patients among
those with ASCVD risk <5% to inform treatment
decision-making, because 25 patients will need to be
scanned to inﬂuence the treatment decision, its utility
in this group is likely to be limited. At the other end of
the risk spectrum (estimated 10-year risk >20%),
although the presence of CAC ¼ 0 is associated with a
much lower observed event rate of 11% than pre-
dicted, it may not impact the decision to avoid statins
because the risk still remains above the threshold
suggested by the guidelines for treatment (1). By
avoiding testing at the extremes of risk (<5% and
>20%), 49% of study participants with 10-year ASVCD
risk estimates of 5% to 20% can be reclassiﬁed by
the absence of CAC to a risk threshold below that
FIGURE 5 ASCVD and CHD Rates Among Nondiabetics With LDL-C From 70 to 189 mg/dl Across the Spectrum of CAC Burden and
Increasing 10-Year ASCVD Risk >7.5% Categories
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The lowest event rates were noted in those with CAC ¼ 0 across increasing 10-year risk estimates among nondiabetics with LDL 70 to 189 mg/dl (n ¼ 1,822). (A) ASCVD
event rate per 1,000 persons. (B) CHD event rate per 1,000 persons. LDL-C ¼ low-density lipoprotein cholesterol; other abbreviations as in Figures 1, 2, and 3.
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1665suggested for statin therapy (Central Illustration).
In addition, among participants not considered for
statins by current guidelines, such as those >75 years
of age and with LDL-C <70 mg/dl, CAC testing mayhave limited impact because it provided meaningful
risk reclassiﬁcation in approximately 10% of study
participants to inﬂuence the decision regarding
statin use.
CENTRAL ILLUSTRATION Impact of the Absence of CAC in Reclassifying Risk Below the Threshold for Statin Consideration
Suggested by ACC/AHA Cholesterol Management Guidelines Across the Spectrum of Estimated 10-Year ASCVD Risk Score
(Nondiabetic Patients With LDL-C of 70 to 189 mg/dl)
1.3/1,000             2.7/1,000                         1.5/1,000             7.4/1,000                         4.6/1,000            10.4/1,000                    11.7/1,000            14.2/1,000
CAC = 0                CAC >0                              CAC = 0                CAC >0                             CAC = 0                 CAC >0                          CAC = 0                CAC >0 
79%                      21%                                    57%                      43%                                   45%                      55%                               26%                       74%
Statin Not Recommended                               Considered for Statin                                    Recommended Statin                                Recommended Statin
10 Year ASCVD <5%                                  10 Year ASCVD 5-7.5%                                 10 Year ASCVD 7.5-20%                              10 Year ASCVD >20%
        (n = 1,792)                                                       (n = 589)                                                         (n = 1,381)                                                    (n = 441)
Nasir, K. et al. J Am Coll Cardiol. 2015; 66(15):1657–68.
The absence of CAC reclassiﬁes risk below the threshold for statin consideration in 40% (956 of 2,411) of statin candidates (>5% ASCVD estimate), and in
49% (956 of 1,970) of those with ASCVD risk between 5% and 20%. ACC/AHA ¼ American College of Cardiology/American Heart Association; ASCVD ¼
atherosclerotic cardiovascular disease; CAC ¼ coronary artery calcium; LDL-C ¼ low-density lipoprotein cholesterol.
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appropriate candidates for statin therapy is not a
straightforward decision; the pros and cons of this
strategy deserve further discussion. First, with cur-
rent guidelines, nearly two-thirds of U.S. adults areTABLE 3 Estimated 10-Year NNT for an ASCVD and CHD Event by
CAC Burden Across Statin-Eligible Groups
N
ASCVD CHD
*10-Year
NNT (30% RRR)
*10-Year
NNT (30% RRR)
Statin recommended 2,377
CAC ¼ 0 978 64 139
CAC 1-100 714 38 59
CAC >100 685 22 34
Any CAC present 1,399 28 43
Statin considered 589
CAC ¼ 0 338 223 556
CAC 1-100 184 43 67
CAC >100 67 53 71
Any CAC present 251 46 69
Statin not recommended 1,792
CAC ¼ 0 1,417 257 371
CAC 1-100 298 334 1,112
CAC >100 77 35 35
Any CAC present 375 124 159
*30% relative risk reduction from a Cochrane meta-analysis of statin therapy in
primary prevention. Statin recommended: patients aged 45 to 75 years of age with
primary elevations of LDL–C $190 mg/dl, diabetes with LDL-C 70-189 mg/dl,
nondiabetic with LDL-C 70-189 mg/dl, and an estimated 10-year ASCVD risk of
7.5% or higher. Statin considered: 10-year ASCVD risk 5% to <7.5%. Statin not
recommended: 10-year ASCVD <5%.
NNT ¼ number needed to treat; RRR ¼ relative risk reduction; other abbrevia-
tions as in Tables 1 and 2.already candidates (recommended or considered) for
statins. In this setting, screening with CAC testing to
identify additional candidates for preventive treat-
ments is questionable. We believe that the value of
CAC testing in the current era may be in limiting the
scope of statin therapy to more selective use, rather
than in expanding it. Wijns et al. termed this risk-
reduction approach “interventional prevention” (25).
Second, it is important to realize that CAC testing adds
to health care costs. The average national cost for CAC
testing is around $100, which may be equivalent to
18 months of a generic statin priced at $5 per month.
Noncardiac ﬁndings on CAC testing, such as nodules,
can generate recommendations for follow-up imaging
in approximately 5% of adults without a history of
smoking. However, a recent study from MESA has
demonstrated that even accounting for this, it may
still be cost-effective to treat only those with CAC >0,
compared with strategies from established risk-
assessment guidelines (26). There are also concerns
that CAC scoring may lead to additional cardiac
testing and interventions, although a recent report
from the EISNER (Early Identiﬁcation of Subclinical
Atherosclerosis by Noninvasive Imaging Research)
study showed no such trends, with fewer downstream
tests noted among those with CAC ¼ 0 (27). In addi-
tion, the literature supports signiﬁcant lifestyle opti-
mization as well as improved preventive medication
adherence among those with increasing CAC burden
(28). Third, CAC testing is associated with an average
radiation dose of 0.89 mSv compared with back-
ground radiation of 3 mSv per year, which should be
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Nearly one-half
of patients without established atherosclerosis, who are classi-
ﬁed as eligible for statin therapy according to the 2013 ACC/AHA
blood cholesterol guidelines, have no detectable CAC, suggest-
ing that their 10-year risk of clinical events may be lower than
those for whom statin use is generally recommended.
TRANSLATIONAL OUTLOOK: Among candidates for statin
therapy, clinicians should consider the role of CAC testing in
shared decision-making processes to facilitate informed choices
for ﬂexible treatment goals.
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making. Finally, it is also important to note that our
study does not address the issue of whether a
CAC-based strategy versus guideline-based recom-
mendations for statin selection is better or will have
a favorable impact on outcomes; this vital question
needs to be critically tested by well-designed compara-
tive-effectiveness clinical studies.
STUDY LIMITATIONS. Subjects enrolling in research
studies such as MESA may be more health-conscious,
with better general risk proﬁles, and, as a result, have
a lower risk for cardiovascular events. However, on
the basis of risk factor clustering, a similar proportion
of MESA participants were candidates for statin
therapy compared with national estimates. In MESA,
CAC scores were reported to participants and their
physicians, which may have led to extensive risk
modiﬁcation that inﬂuenced ASCVD events. In spite
of these potential early interventions, the 10-year
observed ASCVD risk was consistently above the
threshold for statin recommendation in the presence
of a higher CAC burden.
CONCLUSIONS
Signiﬁcant heterogeneity exists among those eligible
for statins according to the ACC/AHA cholesterol
management guidelines. Approximately one-half of
these candidates have no detectable CAC, and, as a
result, they have a much lower observed 10-year
ASCVD risk and a higher estimated NNT to prevent 1event. These ﬁndings should stimulate discussions
among key stakeholders on the potential role of
CAC ¼ 0 to facilitate shared decision-making pro-
cesses for ﬂexible treatment goals in patients deemed
eligible for lifelong statins.
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